RxDoctor Payments Data

Scott Shapiro, MD

Cardiovascular Disease · Horsham, PANPI 1235247545

Payments from drug & device makers

$312in general payments, 2019–2025

Across 12 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$98
  • Novo Nordisk$94
  • Sanofi-aventis U.S. LLC$52
  • Johnson & Johnson$23
  • E.r. Squibb & Sons, L.L.C.$19
  • Novartis$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$312 in reported general payments places this provider in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$351,234
Medicare patients
1,083
Services billed
3,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban399$393,330
XareltoRivaroxaban201$216,723
EntrestoSacubitril/Valsartan172$174,964
Repatha SureclickEvolocumab24$22,839
MultaqDronedarone Hcl16$22,352
Flecainide Acetate148$10,435
JardianceEmpagliflozin11$9,235
Valsartan274$8,528
Atorvastatin Calcium393$6,916
Ranolazine ErRanolazine37$6,889
Metoprolol Succinate423$6,477
BrilintaTicagrelor11$5,935
Rosuvastatin Calcium347$5,366
Diltiazem 24hr Er (Cd)Diltiazem Hcl144$5,287
Nifedipine ErNifedipine190$4,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$393,330399 claims
Johnson & JohnsonXarelto$23$216,723201 claims
NovartisEntresto$14$174,964172 claims
Sanofi-aventis U.S. LLCMultaq$52$22,35216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Horsham

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →